Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
Giuseppe Derosa, Pamela MaffioliDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, ItalyIntroduction: Targeting glycated hemoglobin (HbA1c) levels below 7.0% is considered a primary goal of diabetes care, given its importance in obtaining a sustained reduction in microvasc...
Guardado en:
Autores principales: | Maffioli P, Derosa G |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/81f3951fab194831b824de5f399d6fbb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
por: Jonathan K Reynolds
Publicado: (2009) -
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Karen Barnard, et al.
Publicado: (2010) -
Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination
por: Fleming JW, et al.
Publicado: (2015) -
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Green J, et al.
Publicado: (2010) -
Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
por: Robert G Moses
Publicado: (2010)